CCM
RNAC icon

Coldstream Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Coldstream Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-29
Closed -$383 – 2864
2025
Q1 		$383 Buy
+29
New +$518 ﹤0.01% 3408

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Coldstream Capital Management's RNAC Position: Q2 2025 in Review

Coldstream Capital Management sold out of Cartesian Therapeutics (RNAC) in Q2 2025, closing a stake of 29 shares — an estimated $383 sold.

Coldstream Capital Management first reported a position in RNAC in Q1 2025 and held it in 1 quarter. The position peaked at $383 in Q1 2025. 66 funds tracked by Wall St. Rank hold RNAC as of Q2 2025.

  • Coldstream Capital Management reported no remaining Cartesian Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 29 Cartesian Therapeutics shares in Q2 2025, an estimated $383.
  • Coldstream Capital Management first reported a position in Cartesian Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Cartesian Therapeutics position peaked at $383 in Q1 2025.
  • 66 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.